The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
India has the second-largest number of adults with diabetes globally, after China
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Ritika has also extensively worked with clients such as WHO, GAVI Alliance, USAID, Gilead, Novartis, Sanofi Pasteur
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Go-ahead for pivotal clinical trial which is expected to commence by March
Narayanan to lead SeQuent through next phase of consolidation and growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)